These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37602144)

  • 1. Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease.
    Amin S; Sangadi I; Allman-Farinelli M; Badve SV; Boudville N; Coolican H; Coulshed S; Foster S; Fernando M; Haloob I; Harris DCH; Hawley CM; Holt J; Howell M; Kumar K; Johnson DW; Lee VW; Mai J; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
    Kidney Med; 2023 Sep; 5(9):100691. PubMed ID: 37602144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
    Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
    Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis.
    Houghton C; Dowling M; Meskell P; Hunter A; Gardner H; Conway A; Treweek S; Sutcliffe K; Noyes J; Devane D; Nicholas JR; Biesty LM
    Cochrane Database Syst Rev; 2020 Oct; 10(10):MR000045. PubMed ID: 33026107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic Kidney Disease-Related Disease Burden in Adolescents With Autosomal Dominant Polycystic Kidney Disease: An International Qualitative Study.
    Oberdhan D; Schaefer F; Cole JC; Palsgrove AC; Dandurand A; Guay-Woodford L
    Kidney Med; 2022 Mar; 4(3):100415. PubMed ID: 35386599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
    Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
    Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.
    Sautenet B; Cho Y; Gutman T; Rangan G; Ong A; Chapman AB; Ahn C; Coolican H; Tze-Wah Kao J; Fowler K; Gansevoort RT; Geneste C; Perrone RD; Harris T; Torres VE; Pei Y; Craig JC; Tong A;
    Am J Kidney Dis; 2020 Aug; 76(2):213-223. PubMed ID: 32171640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
    Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
    Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.
    Chebib FT; Zhou X; Garbinsky D; Davenport E; Nunna S; Oberdhan D; Fernandes A
    Kidney Med; 2023 Jun; 5(6):100639. PubMed ID: 37250503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and study protocol of ACQUIRE, a prospective, observational study measuring quality of life, treatment preference and treatment satisfaction of autosomal dominant polycystic kidney disease (ADPKD) patients in Europe.
    Joly D; Quinn J; Mokiou S; O'Reilly K; Sánchez-Covisa J; Wang-Silvanto J; Doll H
    BMC Nephrol; 2020 Jul; 21(1):298. PubMed ID: 32709218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey.
    El-Damanawi R; Harris T; Sandford RN; Karet Frankl FE; Hiemstra TF
    Clin Kidney J; 2017 Jun; 10(3):305-309. PubMed ID: 28616208
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey.
    Cho Y; Rangan G; Logeman C; Ryu H; Sautenet B; Perrone RD; Nadeau-Fredette AC; Mustafa RA; Htay H; Chonchol M; Harris T; Gutman T; Craig JC; Ong ACM; Chapman A; Ahn C; Coolican H; Kao JT; Gansevoort RT; Torres V; Pei Y; Johnson DW; Viecelli AK; Teixeira-Pinto A; Howell M; Ju A; Manera KE; Tong A
    Am J Kidney Dis; 2020 Sep; 76(3):361-373. PubMed ID: 32359822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.
    Gunn H; Andrade J; Paul L; Miller L; Creanor S; Stevens K; Green C; Ewings P; Barton A; Berrow M; Vickery J; Marshall B; Zajicek J; Freeman J
    Health Technol Assess; 2019 Jun; 23(27):1-166. PubMed ID: 31217069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.
    Brosnahan GM; Wang W; Gitomer B; Struemph T; George D; You Z; Nowak KL; Klawitter J; Chonchol MB
    Am J Kidney Dis; 2022 Apr; 79(4):518-526. PubMed ID: 34391872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.